Experience with Lipofilling in Children with Localized Scleroderma: Case Study
Alina R. Misbakhova,
Nataliya E. Manturova,
Larisa S. Kruglova,
Nikolay N. Murashkin,
Sofiya R. Mayransaeva https://doi.org/10.15690/vsp.v23i5.2812
Abstract
Background. Localized scleroderma (LS) is an inflammatory sclerosing disease of unknown etiology. It is characterized by progressive lesion of connective tissue leading to sclerosis and/or atrophy of the skin and underlying tissues. The LS prevalence is 27 cases per 1 million per year, and 3.4 cases occur in children. Clinical case description. This article presents two clinical cases of LS in children under the age of 12 years. Contour plastic surgery with adipose tissue (lipofilling) was performed in both cases. It was possible to achieve volume correction via lipoaspirate, to increase derma and subcutaneous fat thickness in sclerosis focus, to reduce skin tightness, and to improve microcirculation during the treatment. Conclusion. Surgical management of children with lipofilling allows to eliminate gross facial defects, to increase the subcutaneous fat layer in sclerosis foci. Moreover, these patients report an improvement in psycho-emotional state after autotransplantation of adipose tissue.
Supporting agencies: Not specified.
About the Authors
Alina R. Misbakhova
Institute of Plastic Surgery and Cosmetology
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Nataliya E. Manturova
Institute of Plastic Surgery and Cosmetology
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Janssen, Eli Lilly, Novartis, AbbVie, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderma, L’Oreal, NAOS, Pierre Fabre, Bayer, LEO Pharma, Pfizer, Sanofi, Novartis, AbbVie, Glenmark, Janssen, Invar, Librederm, Viatris, JGL, B.Braun, Swixx BioPharma
Larisa S. Kruglova
Institute of Plastic Surgery and Cosmetology; Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Nikolay N. Murashkin
Central State Medical Academy of Department of Presidential Affairs; National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
Sofiya R. Mayransaeva
Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Other authors confirmed the absence of a reportable conflict of interests
References
1. Li SC, Feldman BM, Higgins GC, et al. Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists. J Rheumatol. 2018;37(1):175–181. doi: https://doi.org/10.3899/jrheum.090708
2. Murashkin NN, Savelova AA, Misbakhova AR. Face Lesions in En Coup De Sabre Scleroderma in Children: Modern Treatment and Outcomes Improvement. Voprosy sovremennoi pediatrii — Current Pediatrics. 2022;21(5):414–418. (In Russ). doi: https://doi.org/10.15690/vsp.v21i5.2460
3. Kubanov АА, Bogdanova EV. Resources and performance rates of medical organizations providing medical care in the field of dermatovenereology in the Russian Federation in 2016–2022. Vestnik Dermatologii i Venerologii. 2023;99(4):18–40. (In Russ). doi: https://doi.org/10.25208/vdv12385
4. Lokalizovannaya sklerodermiya: Clinical guidelines. Russian Society of Dermatovenerologists and Cosmetologists; Association of Rheumatologists of Russia. Ministry of Health of Russian Federation; 2020. 50 p. (In Russ).
5. Verberkt RM, Janssen M, Wesseling J. A boy with a tight skin: Borrelia-associated early-onset morphea. Clin Exp Rheumatol. 2014;32(1):121–122.
6. Ozkan S, Atabey N, Fetil E, et al. Evidence for Borrelia burgdorferi in morphea and lichen sclerosus. Int J Dermatol. 2000;39(4): 278–283. doi: https://doi.org/10.1046/j.1365-4362.2000.00912.x
7. Snarskaya ES, Vasileva KD. Localized scleroderma: actual insights and new biomarkers. Int J Dermatol. 2022;61(6):667–674. doi: https://doi.org/10.1111/ijd.15811
8. Higley H, Persichitte K, Chu S, et al. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Arthritis Rheum. 1994;37(2):278–288. doi: https://doi.org/10.1002/art.1780370218
9. Ihn H, Sato S, Fujimoto M, et al. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res. 1995;287:193–197. doi: https://doi.org/10.1007/BF01262331
10. Kreuter A, Hyun J, Skrygan M, et al. Ultraviolet al-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlate with clinical improvement in localized scleroderma. Br J Dermatol. 2006;155(3):600–607. doi: https://doi.org/10.1111/j.1365-2133.2006.07391.x
11. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol. 2006;140(4):345–356. doi: https://doi.org/10.1159/000094242
12. Gambichler T, Skrygan M, Labanski AA, et al. Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma. Regul Pept. 2011;170(1-3):4–6. doi: https://doi.org/10.1016/j.regpep.2011.05.003
13. Zhao M, Wu J, Wu H, et al. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review, Clinical Reviews. Clin Rev Allergy Immunol. 2022;62(2):273–291. doi: https://doi.org/10.1007/s12016-020-08831-4
14. Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873–2881. doi: https://doi.org/10.1002/art.21264
15. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–396. doi: https://doi.org/10.1016/j.jaad.2008.05.005
16. Tollefson M, Witman P. En coup de sabre morphea and parryromberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007;56(2):257–263. doi: https://doi.org/10.1016/j.jaad.2006.10.959
17. Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67(6):1151–1156. doi: https://doi.org/10.1016/j.jaad.2012.03.036
18. El Omari M, Debbarh M, Lakhdari M, et al. Adipose Tissue Grafting for the Treatment of Morphea En Coup De Sabre: A Simple Filler or an Emerging Cellular Therapy? Cureus. 2022;14(10):e30358. doi: https://doi.org/10.7759/cureus.30358
19. Gheisari M, Ahmadzadeh A, Nobari N, et al. Autologous fat grafting in the treatment of facial scleroderma. Dermatol Res Pract. 2018;2018:6568016. doi: https://doi.org/10.1155/2018/6568016
Review
For citations:
Misbakhova A.R., Manturova N.E., Kruglova L.S., Murashkin N.N., Mayransaeva S.R. Experience with Lipofilling in Children with Localized Scleroderma: Case Study. Current Pediatrics. 2024;23(5):336-342. (In Russ.) https://doi.org/10.15690/vsp.v23i5.2812
Views:
219
Email this article 
